Sinopharm Group Co. Ltd. (SHTDY) Stock Price & Analysis
Sinopharm Group Co. Ltd. (SHTDY) — price $9.40 (+0.40%), as of the Oct 5, 2026 trading session; market cap $5.87B.
Educational signal · not a buy or sell recommendation · How to read this
Sinopharm Group Co. Ltd. · SHTDY · Healthcare · Medical - Distribution
Sinopharm Group Co. Ltd. is a prominent Chinese enterprise specializing in the wholesale and retail of pharmaceuticals, medical devices, and other healthcare products.
Price as of Oct 5, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $9.40 | |
| Change on the day | +0.40% | |
| 52-week range | $9.05 – $14.87 | |
| Market capitalisation | $5.87B | |
| Price / earnings (trailing) | 5.66 | |
| Shares traded on the day | 1.1K | |
| Beta (volatility vs the S&P 500) | 0.45 | |
| Dividends per share (last 12 months) | $0.50 | |
| Dividend yield (last 12 months) | 5.37% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Other perspectives
Council score for Sinopharm Group Co. (SHTDY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the SHTDY film — every key number, told as a short cinematic story
~2 min · open the film
What is Sinopharm Group Co. (SHTDY), and what does it report?
Short answer · as of
Sinopharm Group Co. Ltd. is a prominent Chinese enterprise specializing in the wholesale and retail of pharmaceuticals, medical devices, and other healthcare products. Healthcare / Medical Distribution Headquarters: Sinopharm Group Building, Shanghai, SH, 200023, CN. It employs 94,910 people and is led by Wanyong Lian. In Q2 FY2026 it reported revenue of $41.80B and net income of $503M. The market values it at $5.87B.
What do the latest results show for Sinopharm Group Co. (SHTDY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $41.80B. Against analyst estimates the company has EPS beat 3 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $321.76B Apr 23, 2026
- Latest report · revenue estimate
- $315.53B Apr 23, 2026
- Latest report · revenue vs estimate
- Above estimate Apr 23, 2026
- Latest report · EPS vs estimate
- Above estimate Apr 23, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Apr 23, 2026 | $321.76B | $315.53B | $1.3100 | $1.2700 |
| Aug 21, 2025 | $312.96B | $316.41B | $1.2100 | $1.0600 |
| Mar 20, 2025 | $308.27B | $314.43B | $1.1400 | $1.5000 |
| Oct 25, 2024 | $316.51B | $334.10B | $1.2800 | $1.4800 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $41.80B | $503M | $0.80 (diluted) |
| Q4 FY2025 | $42.41B | $541M | $0.87 (diluted) |
| Q2 FY2025 | $42.75B | $517M | $0.83 (diluted) |
| Q4 FY2024 | $43.30B | $500M | $0.80 (diluted) |
What are the financial strengths and risks for Sinopharm Group Co. (SHTDY)?
Short answer
The distress and quality screens read Altman Z 3.70 · Piotroski F 7. Trailing ratios: ROE 8.3% · ROA 1.7% · current ratio 1.40 · earnings yield 17.8% · free-cash-flow yield 47.3%.
Common Questions About SHTDY (Healthcare)
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What do fundamental quality screens indicate about earnings sustainability?
Standard financial solvency screens like the Piotroski F-score and Altman Z-score indicate that Sinopharm faces low bankruptcy risk and maintains adequate balance-sheet quality. However, these screens measure financial solvency, not the sustainability of operating margins, which depends on competitive and regulatory factors that balance sheets do not capture.
What is the SHTDY stock price today?
The last price recorded on this page for Sinopharm Group Co. Ltd. (SHTDY) is $9.40, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Does SHTDY pay a dividend?
Yes. Sinopharm Group Co. Ltd. (SHTDY) shows a trailing 12-month dividend yield of 5.37%, as of Oct 2, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (39 figures)
The 39 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 31 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $9.40 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-06T12:44:43.181Z. | |
px.change | Change on the day | +0.40% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $5.87B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T20:00:00.000Z. Captured from FMP at 2026-10-06T12:44:41.734Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
id.business_summary | Business description (FMP excerpt) | Sinopharm Group Co. Ltd. is a prominent Chinese enterprise specializing in the wholesale and retail of pharmaceuticals, medical devices, and other healthcare products. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | +$0.037 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 5.66 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 1.1K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.45 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Medical Distribution | FMP | Financial Modeling Prep (FMP) company profile | |
id.hq | Headquarters | Sinopharm Group Building, Shanghai, SH, 200023, CN | FMP | Financial Modeling Prep (FMP) company profile | |
id.employees | Employees | 94,910 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Wanyong Lian | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_revenue | Revenue, Q2 FY2026 | $41.80B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | $503M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-04-23.revenue_actual | Revenue · reported — report date 2026-04-23 | $321.76B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-23.revenue_estimated | Revenue · estimate — report date 2026-04-23 | $315.53B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-23.eps_actual | EPS · reported — report date 2026-04-23 | $1.3100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-23.eps_estimated | EPS · estimate — report date 2026-04-23 | $1.2700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-08-21.revenue_actual | Revenue · reported — report date 2025-08-21 | $312.96B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-08-21.revenue_estimated | Revenue · estimate — report date 2025-08-21 | $316.41B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-08-21.eps_actual | EPS · reported — report date 2025-08-21 | $1.2100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-08-21.eps_estimated | EPS · estimate — report date 2025-08-21 | $1.0600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-03-20.revenue_actual | Revenue · reported — report date 2025-03-20 | $308.27B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-03-20.revenue_estimated | Revenue · estimate — report date 2025-03-20 | $314.43B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-03-20.eps_actual | EPS · reported — report date 2025-03-20 | $1.1400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-03-20.eps_estimated | EPS · estimate — report date 2025-03-20 | $1.5000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2024-10-25.revenue_actual | Revenue · reported — report date 2024-10-25 | $316.51B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2024-10-25.revenue_estimated | Revenue · estimate — report date 2024-10-25 | $334.10B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2024-10-25.eps_actual | EPS · reported — report date 2024-10-25 | $1.2800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2024-10-25.eps_estimated | EPS · estimate — report date 2024-10-25 | $1.4800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $9.05 – $14.87 | UNRECORDED | Stored company-profile observation — Captured 2026-10-05 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 3 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-08-16 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 3.70 · Piotroski F 7 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 8.3% · ROA 1.7% · current ratio 1.40 · earnings yield 17.8% · free-cash-flow yield 47.3% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 4 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.50 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 1 split-adjusted declared dividend with an ex-date in the 365 days to 2026-10-05, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 5.37% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-04-23.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($321.76B) with the recorded estimate ($315.53B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-04-23.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($1.3100) with the recorded estimate ($1.2700) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
Fact-family notes
- Earnings-history note. Source series as of 2026-04-23. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-04-23.revenue_actual,earn.history.depth.2026-04-23.revenue_estimated,earn.history.depth.2026-04-23.revenue_actual.comparison,earn.history.depth.2026-04-23.eps_actual.comparison,earn.history.depth.2026-04-23.eps_actual,earn.history.depth.2026-04-23.eps_estimated,earn.history.depth.2025-08-21.revenue_actual,earn.history.depth.2025-08-21.revenue_estimated,earn.history.depth.2025-08-21.eps_actual,earn.history.depth.2025-08-21.eps_estimated,earn.history.depth.2025-03-20.revenue_actual,earn.history.depth.2025-03-20.revenue_estimated,earn.history.depth.2025-03-20.eps_actual,earn.history.depth.2025-03-20.eps_estimated,earn.history.depth.2024-10-25.revenue_actual,earn.history.depth.2024-10-25.revenue_estimated,earn.history.depth.2024-10-25.eps_actual,earn.history.depth.2024-10-25.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Distress and quality screens | Altman Z-score: 3.7; Piotroski F-score: 7 Altman Z below 1.8 is the conventional distress zone. The screen is built for manufacturers and industrials; for banks, insurers and property companies it is not a meaningful reading. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) financial scores |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-04-23 | FMP | Financial Modeling Prep (FMP) earnings |
| Trailing twelve-month ratio set | Quick ratio: 1.14; Current ratio: 1.4; Debt to equity: 1.34; Net margin: 1.2%; Gross margin: 7%; Operating margin: 3%; Return on assets: 1.7%; Return on equity: 8.3% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
Data provided for informational purposes only.